HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation
Authors:
- Monika Skrzypiec-SpringMSMonika Skrzypiec-Spring
- Agnieszka Sapa-WojciechowskaASAgnieszka Sapa-Wojciechowska
- Katarzyna Haczkiewicz-LeśniakKHKatarzyna Haczkiewicz-Leśniak
- Tomasz PiaseckiTPTomasz Piasecki
- Joanna KwiatkowskaJKJoanna Kwiatkowska
- Marzenna Podhorska-OkołówMPMarzenna Podhorska-Okołów
- Adam SzelągASAdam Szeląg
Open Access
- 28 September 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (10) , 1415
Abstract
Background: Acute myocarditis often progresses to heart failure because there is no effective, etiology-targeted therapy of this disease. Simvastatin has been shown to be cardioprotective by decreasing matrix metalloproteinases’ (MMPs) activity. The study was designed to determine whether simvastatin inhibits MMPs activity, decreases the severity of inflammation and contractile dysfunction of the heart in experimental autoimmune myocarditis (EAM). Methods: Simvastatin (3 or 30 mg/kg/day) was given to experimental rats with EAM by gastric gavage for 21 days. Then transthoracic echocardiography was performed, MMPs activity and troponin I level were determined and tissue samples were assessed under a light and transmission electron microscope. Results: Hearts treated with simvastatin did not show left ventricular enlargement. As a result of EAM, there was an enhanced activation of MMP-9, which was significantly reduced in the high-dose simvastatin group compared to the low-dose group. It was accompanied by prevention of myofilaments degradation and reduction of severity of inflammation. Conclusions: The cardioprotective effects of simvastatin in the acute phase of EAM are, at least in part, due to its ability to decrease MMP-9 activity and subsequent decline in myofilaments degradation and suppression of inflammation. These effects were achieved in doses equivalent to therapeutic doses in humans.Keywords
This publication has 42 references indexed in Scilit:
- Effects of HMG-CoA Reductase Inhibitor on Experimental Autoimmune MyocarditisCardiovascular Drugs and Therapy, 2012
- Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3Journal of Orthopaedics and Traumatology, 2011
- Atorvastatin Attenuates Coxsackie Virus B3m-induced Viral Myocarditis in MiceJournal of Cardiovascular Pharmacology, 2010
- Increased Activities of Cardiac Matrix Metalloproteinases Matrix Metalloproteinase (MMP)–2 and MMP‐9 Are Associated with Mortality during the Acute Phase of ExperimentalTrypanosoma cruziInfectionThe Journal of Infectious Diseases, 2008
- Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarizationLife Sciences, 2007
- Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis ratsImmunology & Cell Biology, 2006
- HMG-CoA Reductase Inhibitors Reduce Matrix Metalloproteinase-9 Activity in Human Varicose VeinsEuropean Surgical Research, 2005
- HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activationCardiovascular Research, 2004
- The Toxicology of HMG—CoA Reductase Inhibitors: Prediction of Human RiskToxicologic Pathology, 2004
- A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fractionClinical Immunology and Immunopathology, 1990